A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2018
At a glance
- Drugs RO 7049389 (Primary) ; Midazolam
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Roche
- 07 Aug 2017 Planned End Date changed from 1 Aug 2018 to 25 Jan 2019.
- 07 Aug 2017 Planned primary completion date changed from 1 Aug 2018 to 25 Jan 2019.
- 07 Aug 2017 Status changed from not yet recruiting to recruiting.